

Viral Therapeutics Incorporated

[View the current Viral Therapeutics Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10845-Viral+Therapeutics+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/10845-Viral+Therapeutics+Incorporated.html>)

Contact Details:

95 Brown Road

Ithaca

NY

14850

United States of America

Tel: 607 266 0860

Fax: 607 257 6356

Email:

Recent Publications by Viral Therapeutics Incorporated:



- [Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization.](#)
Alphavirus-derived vectors are being developed for vaccine, gene therapy... 10th May, 2008
Department of Viral Therapeutics and Department of Immunobiology, Chiron- IDrugs. 1998
Oct;1(6):678-85.
- [Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.](#)
We assessed the activities of 24 different antiviral compounds against... 31st July, 2003
Department of Viral Therapeutics, Virology Division, U.S. Army Medical- Antiviral Res. 2003
Jan;57(1-2):13-23.
- [3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice.](#)
3-deazaneplanocin A, an analog of adenosine, is a potent inhibitor of... 14th February, 2003
Virology Division, Department of Viral Therapeutics, United States Army- Antiviral Res. 2002
Jul;55(1):151-9.
- [Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor.](#)
Ebola Zaire virus causes lethal hemorrhagic fever in humans, for which... 1st August, 2000
Department of Viral Therapeutics, United States Army Medical Research- Antiviral Res. 2000
Feb;45(2):135-47.

Press Releases on Viral Therapeutics Incorporated:

| | | | |
|---|---------------------|-------------------------|--|
| Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference | 24th November, 2009 | Quest Diagnostics | MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is |
| Prodesse's ProParflu+(TM) Assay Cleared for US Marketing by FDA | 24th November, 2009 | Gen-Probe Incorporated | Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated |
| Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference | 24th November, 2009 | Echo Therapeutics, Inc. | FRANKLIN, Mass., Nov. 24 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, |
| Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio | 24th November, 2009 | Aflac Incorporated | COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by |
| NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director | 24th November, 2009 | NeurogesX, Inc. | SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today |

BioNews Results for Viral Therapeutics Incorporated



- [Immune Targeting Systems Confirms Industry Heavyweight Ken Powell as New Chairman](#)
Pharma Live: Nov 22 2009 3:02PM Matching: viral therapeutics
- [Research and Markets: Hepatitis C Virus and Therapeutics Report - A Global Update of Market...](#)
Forbes.com: Nov 19 2009 5:41PM Matching: viral therapeutics
- [Immune Targeting Systems Confirms Industry Heavyweight Ken Powell as New Chairman](#)
NewsBlaze: Nov 16 2009 11:23AM Matching: viral therapeutics

- [Immune Targeting Systems Confirms Industry Heavyweight Ken Powell as New Chairman](#)
Genetic Engineering News: Nov 16 2009 9:07AM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Genetic Engineering News: Nov 15 2009 6:06PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Freshnews.com: Nov 13 2009 12:29AM Matching: viral therapeutics
- [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
Therapeutics Daily: Nov 12 2009 1:30PM Matching: viral therapeutics
- [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
KOTA Territory News: Nov 12 2009 11:33AM Matching: viral therapeutics
- [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
KSLA: Nov 12 2009 6:04AM Matching: viral therapeutics
- [Viron To Present Data From Phase II Trial At American Heart Association Conference](#)
Medical News Today: Nov 12 2009 6:30PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Yahoo! Canada: Nov 12 2009 10:16PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
[Compound's Anti-Cancer Properties Highlighted at](#)
PR inside: Nov 12 2009 10:13PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
[Compound's Anti-Cancer Properties Highlighted at](#)
PR inside: Nov 12 2009 10:11PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data](#)
Market Wire via MSN Money: Nov 12 2009 9:46PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Stockwatch: Nov 12 2009 9:42PM Matching: viral therapeutics

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

